Adverse Event reporting information can be found in the footer.
STADA Specialty and Biosimilars
STADA Specialty and Biosimilars:
Opening doors to cost-effective, life-changing treatments
At STADA, Thornton & Ross, we offer expertise and outstanding value in Specialty Pharmaceuticals and we are continuously expanding our portfolio. Our biosimilars and specialty medicines enable improved access to treatment for patients across a broad range of therapy areas.
Oncology
Bone Health
Nephrology
Immunology
Ophthalmology
NEW ustekinumab biosimilar
UZPRUVO®▼ (ustekinumab)
Uzpruvo is STADA’s ustekinumab biosimilar and offers a cost-effective alternative to the reference product.1,2
Uzpruvo (ustekinumab) is used for the treatment of moderate to severe Crohn’s disease in adults, moderate to severe active ulcerative colitis in adults, moderate to severe plaque psoriasis in adults, moderate to severe paediatric plaque psoriasis and psoriatic arthritis in adults.1
Kinpeygo® 4mg▼ (modified-release hard capsules budesonide)
Kinpeygo – the only disease-modifying 3 treatment for use in IgA nephropathy3
Kinpeygo is indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.8 g/g)3
XIMLUCI®▼ (ranibizumab)
Our first ophthalmology biosimilar, ranibizumab is a biological medicine that is injected into the eye. XIMLUCI is the ranibizumab biosimilar from STADA Thornton and Ross.6
XIMLUCI is indicated for adult patients, treatment of: neovascular (wet) age-related macular degeneration (AMD); visual impairment due to diabetic macular oedema (DME); proliferative diabetic retinopathy (PDR); visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO); visual impairment due to choroidal neovascularisation (CNV).4
Prescribing Information can be found here
MOVYMIA®▼ (teriparatide)
MOVYMIA the teriparatide biosimilar from Thornton & Ross, STADA. MOVYMIA® is indicated for adults for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture.5
Prescribing Information can be found here
Let’s stay connected!
Want to be the first to hear about the products, services and educational resources we offer, including invitations to webinars and events?
STADA biosimilars: Making effective medicine accessible
STADA: Caring for people’s health as a trusted partner
STADA is a leading European company, established by physicians and pharmacists. Manufacturing and distributing pharmaceuticals for more than 125 years.
Key Facts:
+125 years
years of heritage
+15 years
of biosimilars experience
~120 countries
selling STADA products
+13,000 employees
around the globe
Biosimilars – a lifeline for people with unmet medical needs:
 |
Demonstrate equivalent biological activity to their corresponding reference drugs |
|
Improve cost-effectiveness |
|
Provide alternatives for decision makers (e.g. prescribers, regulators, payers, policymakers) |
|
Enhance treatment accessibility for patients |
Our biosimilars enable improved access to treatment for patients across a broad range of indications
What is a Biosimilar?
A biosimilar is a biologic that is highly similar to another biologic medicine:6
Large molecule with a complex structure
Produced from living cells
Strictly regulated biomanufacturing and quality control
Biosimilars are approved according to the same strict standards of safety, efficacy and tolerability as other medicines:6
Undergo clinical studies
Manufactured in licensed facilities
Approved using the same regulatory pathway as reference product
Biosimilars have been trusted medicines in Europe for over 15 years, since the first European biosimilar approval in 20066
Commissioning framework for best value biological medicines7
The commissioning framework for best value biological medicines sets out NHS England’s ambitions to establish a best value first approach, by accelerating and widening the adoption of best value biological medicines across the NHS.
Of new patients requiring biological medicines will be initiated on the best value biological, where clinically appropriate, within 3 months following its launch
This framework is designed to support the NHS to achieve this.
Excerpt from NHS Commissioning framework for best value biological medicines.7
See full NHS report here
References
- Uzpruvo SmPC. Last accessed: July 2025.
- Cost of Uzpruvo and reference product (Stelara) taken from NHS DM+D. Last accessed: July 2025.
- Kinpeygo 4 mg modified release hard capsules SmPC. Last accessed: July 2025.
- XIMLUCI (ranibizumab) SmPC. Last accessed: July 2025.
- Movymia 20 micrograms/80 microliters solution for injection SmPC. Last accessed: July 2025.
- Biosimilar Medicinces Group. Biosimilar Medicines Handbook. 3rd edition 2016. Last accessed: July 2025.
- Commissioning framework for best value biological medicines . Last accessed: July 2025.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Thornton and Ross Limited by emailing thorntonross@medinformation.co.uk or by calling 01484 848164.
UK-MULT-122(5) | July 2025